AGIOS PHARMACEUTICALS, INC. 8-K

What Happened

• On April 29, 2026, Agios Pharmaceuticals, Inc. (AGIO) announced its results for the quarter ended March 31, 2026 and other business highlights in a press release. The company furnished that press release as Exhibit 99.1 to this Form 8-K under Item 2.02 (Results of Operations and Financial Condition). The filing notes the press release is furnished — not “filed” — for Section 18 liability purposes. The report is signed by CEO Brian Goff.

Key Details

• Date of disclosure: April 29, 2026.
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Filing clarity: Information is furnished (not filed) and thus not subject to Section 18 Exchange Act liability.

Why It Matters

• This 8-K signals Agios has released its quarterly results and any related operational or pipeline updates — items investors commonly watch for impacts on earnings, revenue, guidance, and strategy.
• Investors should read the Exhibit 99.1 press release and monitor the company’s upcoming 10-Q or investor presentation for detailed financial figures, guidance changes, and management commentary.